CICC International: First to give Sanegen Pharmaceuticals (01530) a "buy" rating with a target price of 27 Hong Kong dollars.

Zhixin Finance APP learned that CICC International released a research report stating that Sanonda Pharmaceutical (01530) has considerable long-term potential in its core major product, with innovative research and development results about to be concentrated. The stock was given a "buy" rating, with a target price of HK$27, corresponding to a 20.7 times 2025 PE ratio (excluding the impact of the 707 BD down payment) and a 1.4 times 2025 PEG ratio.